The Medicaid Problem Weighing On Elevance Health Stock

The stock is priced for strength, but a deep and persistent drag from one of its largest divisions could challenge the optimistic narrative.

If you hold Elevance Health (ELV) stock, you've been rewarded for believing in a well-run, diversified health insurer. The stock sits near its 52-week high after a strong run, and management just raised its earnings guidance for the year. But when expectations are this high, it's worth asking what could go wrong. For Elevance, the biggest risk isn't a hypothetical threat from the outside; it's a large, well-known problem deep inside the business that the market seems to be looking past.

The company's story is one of two very different businesses right now. While its Commercial and Medicare Advantage segments are performing well, its large Medicaid division is acting as a significant drag on results. The core risk is that this problem proves larger and more stubborn than investors currently appreciate, forcing a re-evaluation of the company's overall health.

A Negative Margin That Won't Budge

A notable issue is the unprofitability of the Medicaid business. Management's full-year outlook for the segment's operating margin is approximately -1.75%. While executives have labeled 2026 as the "trough year for our Medicaid margin," a negative figure of that magnitude in a core division is a serious headwind. It means other parts of the company must work significantly harder just to offset the losses, pressuring overall profitability and the company's ability to compound earnings.

Even as management points to favorable rate updates from states, they have not improved that negative margin forecast. This disconnect suggests that underlying cost pressures from utilization and member acuity remain high. If better revenue from rates is being entirely consumed by higher costs, it raises questions about how quickly this business can actually return to being a contributor to the bottom line.

Shrinking the Problem Isn't a Growth Story

The company's strategy for dealing with the unprofitable parts of this business is, in some cases, to simply walk away. Elevance recently announced a "mutual agreement to exit the D.C. Medicaid market" and stated that it expects to "exit additional Medicaid markets over the next 12-18 months" where it doesn't see a path to sustainable profits. While this is a disciplined financial move to mitigate losses, it's also a defensive one.

Exiting markets shrinks the company's revenue base and addressable market. This directly counters the growth narrative that has helped support the stock's valuation. It signals that the issues in some regions are structural rather than merely a temporary dip. This creates an overhang for investors: which market might be next, and what does that say about the long-term growth potential of a segment that is supposed to be a core part of the portfolio?

Elevance's stock price seems to reflect the strength of its other divisions. But the company's ability to deliver on its promise of at least 12% adjusted EPS growth in 2027 depends on the Medicaid business not being a permanent anchor. The key thing to watch is whether that -1.75% margin begins to meaningfully improve, or if the list of market exits continues to grow.

What Is The Options Market Pricing Into Your Holdings?

A threat like this is a reminder that every stock you own carries risk you cannot always see coming, and the options market puts a number on exactly that uncertainty: the expected move it prices in for the year ahead. Our Expected Move screen shows which S&P 500 names carry the widest priced-in swings, so you can see whether the rest of your portfolio is sitting on risk you have not accounted for. And if you would rather not carry this one name's risk alone, a healthcare ETF like XLV spreads it across the whole group.

ELV Has Fallen 50% From A Peak Before

A threat like the one above is a footnote for a diversified holder and a headline for a concentrated one. ELV itself has fallen 50% from a peak within the past five years, and a fall like that lands very differently when one position carries too much of your wealth. Knowing what a repeat would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.